CA2270431A1 - Method for the detection of compounds that modulate the effects of the obese (ob) protein - Google Patents

Method for the detection of compounds that modulate the effects of the obese (ob) protein Download PDF

Info

Publication number
CA2270431A1
CA2270431A1 CA002270431A CA2270431A CA2270431A1 CA 2270431 A1 CA2270431 A1 CA 2270431A1 CA 002270431 A CA002270431 A CA 002270431A CA 2270431 A CA2270431 A CA 2270431A CA 2270431 A1 CA2270431 A1 CA 2270431A1
Authority
CA
Canada
Prior art keywords
cell line
protein
derived cell
response element
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002270431A
Other languages
English (en)
French (fr)
Inventor
Lee James Beeley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9622870.5A external-priority patent/GB9622870D0/en
Priority claimed from GBGB9622868.9A external-priority patent/GB9622868D0/en
Priority claimed from GBGB9622865.5A external-priority patent/GB9622865D0/en
Priority claimed from GBGB9622866.3A external-priority patent/GB9622866D0/en
Priority claimed from GBGB9622850.7A external-priority patent/GB9622850D0/en
Priority claimed from GBGB9622851.5A external-priority patent/GB9622851D0/en
Priority claimed from GBGB9622849.9A external-priority patent/GB9622849D0/en
Priority claimed from GBGB9622869.7A external-priority patent/GB9622869D0/en
Priority claimed from GBGB9622847.3A external-priority patent/GB9622847D0/en
Priority claimed from GBGB9622848.1A external-priority patent/GB9622848D0/en
Priority claimed from GBGB9622867.1A external-priority patent/GB9622867D0/en
Application filed by Individual filed Critical Individual
Publication of CA2270431A1 publication Critical patent/CA2270431A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA002270431A 1996-11-01 1997-10-30 Method for the detection of compounds that modulate the effects of the obese (ob) protein Abandoned CA2270431A1 (en)

Applications Claiming Priority (23)

Application Number Priority Date Filing Date Title
GBGB9622865.5A GB9622865D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622866.3 1996-11-01
GB9622869.7 1996-11-01
GB9622847.3 1996-11-01
GBGB9622866.3A GB9622866D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622850.7A GB9622850D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622868.9 1996-11-01
GB9622849.9 1996-11-01
GB9622851.5 1996-11-01
GB9622850.7 1996-11-01
GBGB9622851.5A GB9622851D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622870.5A GB9622870D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622867.1A GB9622867D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622868.9A GB9622868D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622865.5 1996-11-01
GBGB9622848.1A GB9622848D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622867.1 1996-11-01
GB9622870.5 1996-11-01
GBGB9622847.3A GB9622847D0 (en) 1996-11-01 1996-11-01 Novel method
GB9622848.1 1996-11-01
GBGB9622869.7A GB9622869D0 (en) 1996-11-01 1996-11-01 Novel method
GBGB9622849.9A GB9622849D0 (en) 1996-11-01 1996-11-01 Novel method
PCT/GB1997/002988 WO1998020158A1 (en) 1996-11-01 1997-10-30 Method for the detection of compounds that modulate the effects of the obese (ob) protein

Publications (1)

Publication Number Publication Date
CA2270431A1 true CA2270431A1 (en) 1998-05-14

Family

ID=27581686

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002270431A Abandoned CA2270431A1 (en) 1996-11-01 1997-10-30 Method for the detection of compounds that modulate the effects of the obese (ob) protein

Country Status (13)

Country Link
EP (1) EP0951564A1 (no)
JP (1) JP2001503982A (no)
KR (1) KR20000053007A (no)
AR (1) AR010262A1 (no)
AU (1) AU4789297A (no)
CA (1) CA2270431A1 (no)
CZ (1) CZ149999A3 (no)
IL (1) IL129685A0 (no)
NO (1) NO992107L (no)
NZ (1) NZ335489A (no)
PL (1) PL333187A1 (no)
TR (1) TR199900963T2 (no)
WO (1) WO1998020158A1 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1293533B1 (it) * 1997-07-14 1999-03-01 Angeletti P Ist Richerche Bio Metodo per la selezione di molecole in grado di mimare, inibire o potenziare gli effetti della interazione tra leptina e cellule che
GB9814199D0 (en) * 1998-06-30 1998-08-26 Univ Buckingham Novel method
AU756617B2 (en) 1998-07-28 2003-01-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Leptin-mediated gene-induction
GB9828087D0 (en) * 1998-12-18 1999-02-17 Smithkline Beecham Plc Novel method
DE60112282T2 (de) 2000-05-22 2006-04-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Auf rezeptorgrundlage arbeitende screening-verfahren für protein wechselwirkungen
GB0019327D0 (en) * 2000-08-08 2000-09-27 Buchanan Baillie Hamilton Paul Slimming system
CA2585549A1 (en) 2004-11-18 2006-05-26 Vib Vzw Novel type leptin receptor antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor
US6068976A (en) * 1995-03-20 2000-05-30 Ligand Pharmaceuticals Incorporated Modulators of ob gene and screening methods therefor
US5712094A (en) * 1995-03-27 1998-01-27 Ligand Pharmaceuticals, Inc. Methods for detecting modulators of cytokine action
TR199701469T1 (xx) * 1995-05-30 1998-03-21 Smithkline Beecham P.L.C �i�man (OB) proteinin etkilerini de�i�tiren bile�imlerin meydana ��kar�lmas� i�in y�ntem.
WO1997040380A1 (en) * 1996-04-22 1997-10-30 Merck & Co., Inc. Leptin assay

Also Published As

Publication number Publication date
NO992107L (no) 1999-06-30
TR199900963T2 (xx) 1999-08-23
PL333187A1 (en) 1999-11-22
EP0951564A1 (en) 1999-10-27
KR20000053007A (ko) 2000-08-25
AR010262A1 (es) 2000-06-07
JP2001503982A (ja) 2001-03-27
IL129685A0 (en) 2000-02-29
AU4789297A (en) 1998-05-29
WO1998020158A1 (en) 1998-05-14
NZ335489A (en) 2001-01-26
CZ149999A3 (cs) 1999-10-13
NO992107D0 (no) 1999-04-30

Similar Documents

Publication Publication Date Title
Inui et al. Androgen‐inducible TGF‐β1 from balding dermal papilla cells inhibits epithelial cell growth: a clue to understanding paradoxical effects of androgen on human hair growth
Murphy et al. Neuroendocrine regulation of the hypothalamic pituitary adrenal axis by the nurr1/nur77 subfamily of nuclear receptors
Albanese et al. Development of a bioassay for FSH using a recombinant human FSH receptor and a cAMP responsive luciferase reporter gene
Brasier et al. Synergistic enhansons located within an acute phase responsive enhancer modulate glucocorticoid induction of angiotensinogen gene transcription
AU715215B2 (en) Method for the detection of compounds that modulate the effects of the obese protein
KIM et al. Angiotensin II-responsive element is the insulin-responsive element in the adipocyte fatty acid synthase gene: role of adipocyte determination and differentiation factor 1/sterol-regulatory-element-binding protein 1c
Rydziel et al. Cortisol represses insulin-like growth factor II receptor transcription in skeletal cell cultures
González et al. Mechanisms of the regulation of EGF receptor gene expression by calcitriol and parathyroid hormone in UMR 106-01 cells
CA2270431A1 (en) Method for the detection of compounds that modulate the effects of the obese (ob) protein
Harada et al. Osteogenic protein-1 up-regulation of the collagen X promoter activity is mediated by a MEF-2-like sequence and requires an adjacent AP-1 sequence
Brunetti et al. Human diabetes associated with defects in nuclear regulatory proteins for the insulin receptor gene.
Monla et al. Cell type-specific regulation of transcription by cyclic adenosine 3,'5'-monophosphate-responsive elements within the calcitonin promoter.
De Groot et al. Up-regulation of Jun/AP-1 during differentiation of N1E-115 neuroblastoma cells
MXPA97009360A (en) Method for the detection of compounds that modulate the effects of the obesi protein
US20030224456A1 (en) Method for the detection of compounds that modulate the effects of the obese (OB) protein
WO1993022331A9 (en) Human crabp-i and crabp-ii
EP0640093A1 (en) Human crabp-i and crabp-ii
Quarles et al. Developmental regulation of osteocalcin expression in MC3T3‐E1 osteoblasts: Minimal role of the proximal E‐box cis‐acting promoter elements
BILLESTRUP et al. Molecular mechanism of growth hormone signalling
Lynch et al. Transforming growth factor-β1 induces transforming growth factor-α promoter activity and transforming growth factor-α secretion in the human colon adenocarcinoma cell line FET
US20020068300A1 (en) Method for the detection of compounds that modulate the effects of the obese protein
US20040038315A1 (en) Novel method
EP1141396A2 (en) Reporter gene assay for compounds which mimic or inhibit the physiological effect of the ob-protein
MXPA99004184A (en) Method for the detection of compounds that modulate the effects of the obese (ob) protein
Catterall et al. Differential regulation of specific gene expression in mouse kidney by androgens and antiandrogens

Legal Events

Date Code Title Description
FZDE Discontinued